Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RNA interference for treating haematological malignancies.

Elizabeth O Hexner1, Alan M Gewirtz

  • 1Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Expert Opinion on Biological Therapy
|December 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Blood immunology & cellular therapy·2026
Same author

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Nature biomedical engineering·2026
Same author

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.

Blood advances·2026
Same author

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Blood advances·2026
Same author

Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.

Leukemia·2025
Same author

Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer.

Cell reports. Medicine·2025

RNA interference (RNAi) offers a promising gene silencing therapy for blood cancers. Overcoming challenges like immune response and delivery is key for successful human trials.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Hematology

Background:

  • RNA interference (RNAi) is a gene silencing mechanism with therapeutic potential.
  • RNAi is gene-specific, potent, and minimally toxic, making it suitable for treating hematological malignancies.

Purpose of the Study:

  • To review the current state of RNA interference (RNAi) for treating hematological malignancies.
  • To discuss the challenges and progress in translating RNAi technology to human clinical trials.

Main Methods:

  • Review of existing laboratory and translational research on RNAi.
  • Analysis of fundamental mechanisms and clinical application hurdles.

Main Results:

  • RNAi demonstrates significant promise for treating blood cancers due to its specificity and potency.

Related Experiment Videos

  • Key challenges for human trials include managing immune responses, target selection, molecule design, and delivery/safety.

    • Conclusions:

    • Translational research is actively addressing the hurdles for clinical RNAi application in hematological malignancies.
    • Continued research is essential to fully realize the therapeutic potential of RNAi in treating blood cancers.